Loading provider…
Loading provider…
Medical Oncology Physician in Chicago, IL
NPI: 1003087768Primary Practice Location
RUSH UNIVERSITY MEDICAL CENTER
1620 W Harrison St, Chicago, IL
Primary Employer
Rush University Internists
rush.edu
HQ Phone
Get MD Marta's Phone Numberphone_androidMobile
Get MD Marta's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
IL State Medical License
2005 - 2026

American Board of Internal Medicine
Medical Oncology
Rush University Medical Center
Fellowship • Hematology and Medical Oncology
2005 - 2008
Residency • Internal Medicine
2002 - 2005
Rush Medical College
rushu.rush.edu
Medical School
Until 2002
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 243 | 701 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 58 | 67 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 37 | 37 |
| 4 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 24 | 26 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 16 | 29 |
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients
Authors: Philip Bonomi, Mary Fidler
Publication Date: 2018-03
The clinical utility of next-generation sequencing for bone and soft tissue sarcoma.
Authors: Steven Gitelis, Charles Gusho, Mia Weiss, Dian Wang, Alan Blank
Journal: Acta Oncol
Publication Date: 2021-10-22
Authors: Matthew Colman, Steven Gitelis, Alan Blank
Journal: J Surg Oncol
Publication Date: 2022-01-13
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel, PROCEDURE: Computed Tomography, DRUG: Cabozantinib S-malate, PROCEDURE: FDG-Positron Emission Tomography
Lead Sponsor: Inhibrx Biosciences, Inc
Intervention / Treatment: DRUG: Placebo, DRUG: INBRX-109
Lead Sponsor: Rush University Medical Center
Collaborators: AstraZeneca
Intervention / Treatment: DRUG: Durvalumab